Purchase this article with an account.
M. Ren, R.P. A. Manzano, G.A. Peyman, P. Khan, P. Carvounis, M. Kivilcim; Inhibition of Experimental Angiogenesis of Cornea by Bevacizumab . Invest. Ophthalmol. Vis. Sci. 2006;47(13):1638.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To evaluate the effect of topically administered bevacizumab (Avastin) on experimental corneal neovascularization in rats.
Silver nitrate sticks (75% silver nitrate, 25% potassium nitrate) was used to perform chemical cauterization of the cornea of 16 eyes of 16 male Long–Evans (LE) rats. For the following 7 days, the 10 eyes in the treatment group received twice daily instillation of Bevacizumab 4mg/ml drops while the 6 eyes in the control group received placebo (normal saline drops twice daily). Digital photographs of the cornea were analyzed to determine the area of cornea covered by neovascularization as a percentage of the total corneal area.
In the Bevacizumab treated eyes, neovascularization covered, on average, 38.2 ± 15.5% (mean ± standard deviation[SD]) of the corneal surface compared with 63.5 ± 5.0% (mean ± SD) in the control group (p=0.0005, Student’s t–test).
Topically administered Bevacizumab (Avastin) at a concentration of 4mg/ml limits corneal neovascularization following chemical injury in the male Long–Evans rat model.
This PDF is available to Subscribers Only